Companies › Savara
1 active drug program in 2 registered trials: 2 Phase 3; Immunology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Regramostim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04544293 | Regramostim | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | Immunology | May 2027 |
| NCT06431776 | Regramostim | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | Immunology | Jun 2027 |
Cash and short-term investments of $130m on 2026-09-30; operating cash outflow about $141m a year; runway about 11 months at that burn, to Aug 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Nanjing King-Friend Biochemical Pharmaceutical CSL Behring Spectrum Pharmaceuticals Qilu Pharmaceutical Kexing Biopharm Yaqrit
Alumis Quoin Pharmaceuticals Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.